The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results of a phase I dose-escalation study of ON 01910.Na in combination with oxaliplatin in patients with advanced solid tumors.
T. Ohnuma
Research Funding - Onconova Therapeutics
J. F. Holland
Consultant or Advisory Role - Onconova Therapeutics
Research Funding - Onconova Therapeutics
S. Goel
No relevant relationships to disclose
E. Wilck
No relevant relationships to disclose
D. Lehrer
No relevant relationships to disclose
M. H. Ghalib
No relevant relationships to disclose
I. Chaudhary
No relevant relationships to disclose
F. Wilhelm
Employment or Leadership Position - Onconova Therapeutics
Stock Ownership - Onconova Therapeutics
U. Swami
No relevant relationships to disclose
S. Mani
Research Funding - Onconova Therapeutics